T. Rowe Price Associates’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $100K | Buy |
37,213
+1,002
| +3% | +$2.69K | ﹤0.01% | 2889 |
|
|
2025
Q1 | $52K | Buy |
36,211
+7,380
| +26% | +$10.6K | ﹤0.01% | 2919 |
|
|
2024
Q4 | $58K | Hold |
28,831
| – | – | ﹤0.01% | 2906 |
|
|
2024
Q3 | $91K | Buy |
28,831
+6,355
| +28% | +$20.1K | ﹤0.01% | 2835 |
|
|
2024
Q2 | $0 | Buy |
+22,476
| New | – | ﹤0.01% | 2924 |
|
|
2023
Q3 | – | Sell |
-1,221,838
| Closed | -$2.63M | – | 2886 |
|
|
2023
Q2 | $2.63M | Sell |
1,221,838
-84,600
| -6% | -$182K | ﹤0.01% | 1379 |
|
|
2023
Q1 | $2.55M | Sell |
1,306,438
-180,867
| -12% | -$353K | ﹤0.01% | 1382 |
|
|
2022
Q4 | $5.71M | Buy |
1,487,305
+296,551
| +25% | +$1.14M | ﹤0.01% | 1161 |
|
|
2022
Q3 | $5.74M | Sell |
1,190,754
-770,456
| -39% | -$3.71M | ﹤0.01% | 1171 |
|
|
2022
Q2 | $15.6M | Sell |
1,961,210
-501,426
| -20% | -$3.99M | ﹤0.01% | 1230 |
|
|
2022
Q1 | $36.2M | Sell |
2,462,636
-388,801
| -14% | -$5.71M | ﹤0.01% | 1072 |
|
|
2021
Q4 | $57.6M | Buy |
2,851,437
+22,697
| +0.8% | +$458K | 0.01% | 952 |
|
|
2021
Q3 | $76.8M | Buy |
2,828,740
+166,155
| +6% | +$4.51M | 0.01% | 859 |
|
|
2021
Q2 | $64.8M | Sell |
2,662,585
-83,209
| -3% | -$2.03M | 0.01% | 941 |
|
|
2021
Q1 | $67M | Buy |
2,745,794
+780,033
| +40% | +$19M | 0.01% | 891 |
|
|
2020
Q4 | $62.9M | Buy |
1,965,761
+1,246,586
| +173% | +$39.9M | 0.01% | 872 |
|
|
2020
Q3 | $23.7M | Buy |
719,175
+126,924
| +21% | +$4.19M | ﹤0.01% | 1109 |
|
|
2020
Q2 | $27.7M | Buy |
+592,251
| New | +$27.7M | ﹤0.01% | 1042 |
|